DK91692D0 - Halogenerede nucleosidderivater, saadanne forbindelser til anvendelse mod en adenovirusinfektion, anvendelse af forbindelserne til fremstilling af et laegemiddel mod en adenovirusinfektion, farmaceutiske praeparater indeholdende forbindelserne samt fremgangsmaade til fremstilling af forbindelserne - Google Patents

Halogenerede nucleosidderivater, saadanne forbindelser til anvendelse mod en adenovirusinfektion, anvendelse af forbindelserne til fremstilling af et laegemiddel mod en adenovirusinfektion, farmaceutiske praeparater indeholdende forbindelserne samt fremgangsmaade til fremstilling af forbindelserne

Info

Publication number
DK91692D0
DK91692D0 DK92916A DK91692A DK91692D0 DK 91692 D0 DK91692 D0 DK 91692D0 DK 92916 A DK92916 A DK 92916A DK 91692 A DK91692 A DK 91692A DK 91692 D0 DK91692 D0 DK 91692D0
Authority
DK
Denmark
Prior art keywords
halogies
halogicative
halogically
derivated
substitutes
Prior art date
Application number
DK92916A
Other languages
English (en)
Other versions
DK169437B1 (da
DK91692A (da
Inventor
John William Talbot Selway
Iii Lowrie Miller Beacham
Susan Mary Daluge
Joel Van Tuttle
Thomas Anthony Krenistky
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of DK91692D0 publication Critical patent/DK91692D0/da
Publication of DK91692A publication Critical patent/DK91692A/da
Application granted granted Critical
Publication of DK169437B1 publication Critical patent/DK169437B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK091692A 1987-08-22 1992-07-14 Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen DK169437B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8719877 1987-08-22
GB878719877A GB8719877D0 (en) 1987-08-22 1987-08-22 Antiviral compounds

Publications (3)

Publication Number Publication Date
DK91692D0 true DK91692D0 (da) 1992-07-14
DK91692A DK91692A (da) 1992-07-14
DK169437B1 DK169437B1 (da) 1994-10-31

Family

ID=10622673

Family Applications (3)

Application Number Title Priority Date Filing Date
DK468288A DK169657B1 (da) 1987-08-22 1988-08-19 Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
DK091692A DK169437B1 (da) 1987-08-22 1992-07-14 Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen
DK140393A DK140393A (da) 1987-08-22 1993-12-17 Ioderet uracilnicleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutisk præparater indeholdende forbindelsen samt fremgangsmåde til fremstilling af forbindelsen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK468288A DK169657B1 (da) 1987-08-22 1988-08-19 Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK140393A DK140393A (da) 1987-08-22 1993-12-17 Ioderet uracilnicleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutisk præparater indeholdende forbindelsen samt fremgangsmåde til fremstilling af forbindelsen

Country Status (19)

Country Link
US (2) US5070078A (da)
EP (2) EP0305117B1 (da)
JP (1) JP2634202B2 (da)
KR (1) KR890003382A (da)
AT (1) ATE82681T1 (da)
AU (1) AU613659B2 (da)
CA (1) CA1333361C (da)
DE (1) DE3876174T2 (da)
DK (3) DK169657B1 (da)
ES (1) ES2052732T3 (da)
GB (1) GB8719877D0 (da)
GR (1) GR3006510T3 (da)
HU (1) HU211666A9 (da)
IE (2) IE63655B1 (da)
MX (1) MX9203416A (da)
NZ (1) NZ225881A (da)
PT (1) PT88306B (da)
SG (1) SG26364G (da)
ZA (1) ZA886182B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
GB8726136D0 (en) * 1987-11-07 1987-12-09 Wellcome Found Therapeutic nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1990003978A1 (en) * 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
GB9003543D0 (en) * 1990-02-16 1990-04-11 Wellcome Found Therapeutic nucleosides
US5166327A (en) * 1990-07-31 1992-11-24 Yuki Gosei Kogyo Co., Ltd. Process for producing 3'-deoxy-3-'-fluorothymidine
JP2804184B2 (ja) * 1991-05-14 1998-09-24 シャープ株式会社 ファクシミリ装置
DE4121001C1 (da) * 1991-06-21 1993-05-06 Max-Delbrueck-Centrum Fuer Molekulare Medizin Berlin-Buch, O-1115 Berlin, De
US5341595A (en) * 1992-06-15 1994-08-30 Environmental Growth Chambers Environmental chamber for plant growth analysis
GB9309787D0 (en) * 1993-05-12 1993-06-23 Rhone Poulenc Chemicals Purification of fluoronucleosides
EP0698032B1 (en) * 1993-05-12 1998-07-29 Rhodia Limited Preparation of fluoro-nucleosides and intermediates for use therein
SE503787C2 (sv) * 1994-12-07 1996-09-02 Electrolux Ab Anordning för att tillhandahålla kylda eller frysta varor
US5690202A (en) * 1996-04-15 1997-11-25 Myers; John E. Overrunning clutch mechanism
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6855561B2 (en) * 2001-09-10 2005-02-15 Quidel Corporation Method for adding an apparent non-signal line to a lateral flow assay
US20030236218A1 (en) * 2002-06-12 2003-12-25 Uckun Fatih M. Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
CN1248266C (zh) * 2002-12-26 2006-03-29 邱智铭 一种转动式电开关结构
US7160537B2 (en) * 2003-12-15 2007-01-09 Siemens Medical Solutions Usa, Inc. Method for preparing radiolabeled thymidine having low chromophoric byproducts
US20050131224A1 (en) * 2003-12-15 2005-06-16 Cti Pet Systems, Inc. Method for preparing radiolabeled thymidine
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE103241C (da) *
GB1251828A (da) * 1968-12-19 1971-11-03
DE1913384C2 (de) * 1968-12-20 1982-12-16 Akademie Der Wissenschaften Der Ddr, Ddr 1199 Berlin 1-(2',3'-Didesoxy-3'-fluor-β-D-xylofuranosyl)-thymin, Verfahren zu seiner Herstellung und dieses enthaltende Cytostatica
GB1189973A (en) * 1969-02-14 1970-04-29 Akad Wissenschaften Ddr Cytostatically-Active 2',3'-Didesoxy-3'-Fluoropyrimidine-Nucleosides
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
DD103241A1 (da) * 1972-12-12 1974-01-12
WO1987000719A1 (en) * 1985-07-23 1987-01-29 Wolf, Karl Circuit for starting and operating at least one low-pressure or high-pressure gas discharge lamp with high-frequnency oscillations
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
US4710492A (en) * 1986-06-23 1987-12-01 Yale University 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
DD279407A1 (de) * 1986-07-24 1990-06-06 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels gegen aids
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
EP0332626A1 (en) * 1986-11-21 1989-09-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions for treating viral infections in humans
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
WO1990003978A1 (en) * 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application

Also Published As

Publication number Publication date
DK468288D0 (da) 1988-08-19
DE3876174T2 (de) 1993-04-01
SG26364G (en) 1995-09-18
EP0305117A2 (en) 1989-03-01
DE3876174D1 (de) 1993-01-07
US5376644A (en) 1994-12-27
DK468288A (da) 1989-02-23
JP2634202B2 (ja) 1997-07-23
DK140393D0 (da) 1993-12-17
IE882533L (en) 1989-02-22
MX9203416A (es) 1992-07-01
HU211666A9 (en) 1995-12-28
NZ225881A (en) 1991-03-26
EP0305117A3 (en) 1989-12-27
ATE82681T1 (de) 1992-12-15
PT88306A (pt) 1989-06-30
IE940696L (en) 1989-02-22
US5070078A (en) 1991-12-03
AU2142988A (en) 1989-05-25
EP0479336A1 (en) 1992-04-08
DK169437B1 (da) 1994-10-31
JPS6468325A (en) 1989-03-14
ES2052732T3 (es) 1994-07-16
DK140393A (da) 1993-12-17
ZA886182B (en) 1990-04-25
CA1333361C (en) 1994-12-06
AU613659B2 (en) 1991-08-08
DK169657B1 (da) 1995-01-09
GB8719877D0 (en) 1987-09-30
PT88306B (pt) 1995-12-29
IE63655B1 (en) 1995-05-31
DK91692A (da) 1992-07-14
GR3006510T3 (da) 1993-06-30
EP0305117B1 (en) 1992-11-25
KR890003382A (ko) 1989-04-14

Similar Documents

Publication Publication Date Title
DK91692D0 (da) Halogenerede nucleosidderivater, saadanne forbindelser til anvendelse mod en adenovirusinfektion, anvendelse af forbindelserne til fremstilling af et laegemiddel mod en adenovirusinfektion, farmaceutiske praeparater indeholdende forbindelserne samt fremgangsmaade til fremstilling af forbindelserne
DK118286A (da) Terapeutisk aktive nucleosider, deres anvendelse og farmaceutiske kompositioner indeholdende forbindelserne
DK253988D0 (da) Farmaceutisk praeparat med indhold af eperison eller tolperison, eller et salt deraf, til indgivelse gennem huden
NO160137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.
DK46687A (da) N6-substituerede adenosiner, fremgangsmaade til deres fremstilling og farmaceutisk komposition indeholdende forbindelserne
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
IT7926662A0 (it) Composizione farmaceutica contenente 3,4-di-idro-3-osso-2-chinossaline.
FI811672L (fi) Nya substituerade 3-fenoxi-1-alkoxi-karbonyl-alkylamino-propanol-2-foereningar med beta-receptor haemmande verkan
DE3873011D1 (de) Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate.
FI925745A0 (fi) Interleukin-6-kompositioner och foerfarande foer deras framstaellning
FR2539126B1 (fr) Derives amino-alcoyl-sulfoniques, leur procede de preparation, et compositions pharmaceutiques en renfermant
IT8423517A0 (it) Composizione farmaceutica per combattere infezioni virali, eprocedimento di uso per le infezioni virali.
ES8304152A1 (es) Procedimiento para la obtencion de derivzados de aminociclitol.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
DE3762800D1 (de) Benzhydrylthiomethan-derivate enthaltende therapeutische zusammensetzungen.
IT1095388B (it) Composizione farmaceutica per la somministrazione di pancreatina
IT1208046B (it) Derivati 3-(idrossimetil)isochinolinici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
SE7902393L (sv) Biologiskt aktiva, nya 8 beta-hydrazinometyl-erolinderivat jemte sett for deras framstellning
IT8421627A0 (it) Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo.
ATE78405T1 (de) Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate.
FI823694L (fi) N-substituerade ergolin- och 9,10-didehydro-ergolin-8-karboxiamid-8-aminometyl-derivat, deras framstaellning och deras farmaceutiska komposition
FI885878A (fi) Substituerade tienoimidazolderivat, foerfarande foer deras framstaellning, dessa innehaollande farmaceutiska kompositioner och deras anvaendning som inhibitorer vid avsoendring av magsyra.
ATE7360T1 (de) Zwei-beta-lactam-derivate enthaltende pharmazeutische zusammensetzungen.
IT8124404A0 (it) Derivato della propionilglina, processi per la sua preparazione e composizioni terapeutiche che lo contengono come principio attivo.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed